Treatment of High-Risk Prostate Cancer in Patients with ESRD

Risk Assessment and Classification

The National Comprehensive Cancer Network (NCCN) classifies high-risk prostate cancer based on a Gleason score of 8-10 or PSA >20 ng/mL, which applies to this patient with a Gleason score of 8 1
Patients with ESRD on dialysis at age 65 have a significantly reduced life expectancy of approximately 5-6 years, which is a critical factor in treatment decision-making 2

The NCCN recommends standard treatment options for high-risk localized prostate cancer, including radical prostatectomy with pelvic lymph node dissection, radiation therapy plus androgen deprivation therapy (ADT), or a combination of external beam radiation therapy plus brachytherapy with or without ADT 1
For patients with high-risk disease and a life expectancy >10 years, definitive treatment is generally recommended rather than observation, according to the National Comprehensive Cancer Network (NCCN) 3

Radiation therapy in ESRD patients carries risks including unpredictable PSA kinetics and higher risk for femoral head avascular necrosis, as reported in The Journal of Urology 2
Despite higher complication rates, surgical approaches may still be preferable in ESRD patients compared to radiation therapy, which can cause additional complications in this population, as noted in The Journal of Urology 2

Radical prostatectomy with pelvic lymph node dissection is the preferred treatment for this patient due to the definitive nature of surgery in removing the primary tumor, as recommended by the NCCN 1
Providing pathological staging information that can guide further management is an additional benefit of radical prostatectomy, as reported in The Journal of Urology 2
Avoidance of radiation-related complications in a dialysis-dependent patient is another reason to prefer radical prostatectomy, according to The Journal of Urology 2

If surgery is contraindicated due to comorbidities, external beam radiation therapy with ADT could be considered, but requires careful planning of radiation fields to minimize complications, as noted in The Journal of Urology 2

PSA monitoring after radical prostatectomy should show undetectable levels within 2 months of surgery, as recommended by the NCCN 1
Androgen deprivation therapy, if used, requires careful monitoring in ESRD patients due to altered drug metabolism, as reported in The Journal of Urology 4